{"id":12588,"date":"2017-08-18T09:42:36","date_gmt":"2017-08-18T08:42:36","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=12588"},"modified":"2017-08-18T11:11:37","modified_gmt":"2017-08-18T10:11:37","slug":"spleiselag-pa-ingenuity-pathways-analysis","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2017\/08\/18\/spleiselag-pa-ingenuity-pathways-analysis\/","title":{"rendered":"[:no]Spleiselag p\u00e5 Ingenuity Pathways Analysis[:en]Ingenuity Pathways Analysis[:]"},"content":{"rendered":"<p>[:no]<a href=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-12616 alignleft\" src=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum-240x300.jpg\" alt=\"k2nytt_uke-33_anne-kristin-stavrum\" width=\"176\" height=\"220\" srcset=\"https:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum-240x300.jpg 240w, https:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum.jpg 400w\" sizes=\"auto, (max-width: 176px) 100vw, 176px\" \/><\/a>Er noen interessert i \u00e5\u00a0 \u201dspleise\u201d p\u00e5 en lisens til dataanalyseprogrammet <strong><em><a href=\"https:\/\/www.qiagenbioinformatics.com\/products\/ingenuity-pathway-analysis\/\">Ingenuity Pathways analysis<\/a><\/em><\/strong>?, sp\u00f8r postdoktor Anne-Kristin Stavrum p\u00e5 vegne av sin gruppe, og skriver videre:<\/p>\n<p>I begynnelsen av juli fikk vi tildelt en sum fra de interne sm\u00e5driftsmidlene som ble lyst ut ved instituttet. Pengene \u00f8nsker vi \u00e5 bruke til \u00e5 kj\u00f8pe en lisens til analyseprogrammet <em>Ingenuity Pathway Analysis<\/em> (IPA). En kort beskrivelse av programmet er gjengitt nedenfor.<\/p>\n<p>Midlene som vi fikk fra instituttet, dekker ikke hele bel\u00f8pet til lisens, s\u00e5 vi m\u00e5 legge til litt selv. Det finnes forskjellige lisenstyper. De mest aktuelle er en lisens for \u00e9n bruker eller en lisens for fem brukere. Siden en lisens for fem brukere bare er \u201clitt\u201d dyrere enn en enkelt lisens, \u00f8nsker vi \u00e5 h\u00f8re om der er flere ved instituttet som kunne v\u00e6re interessert i \u00e5 \u201cspleise\u201d p\u00e5 en lisens til fem brukere.<\/p>\n<p>N\u00f8yaktig pris per lisens vil avhenge av eventuelle ekstra pakker som kan kj\u00f8pes, og eventuelle tilbud vi kan f\u00e5 fra <em>Qiagen<\/em>. Prisen vil sannsynligvis ende p\u00e5 kr 13\u201315 000 per lisens, etter at vi har trukket fra bel\u00f8pet vi ble tildelt fra instituttet. Lisensen vil v\u00e6re gyldig i ett \u00e5r.<\/p>\n<p>Interesserte bes kontakte <strong><a href=\"mailto:Anne-Kristin.Stavrum@uib.no\">Anne-Kristin Stavrum<\/a><\/strong> innen <strong>torsdag 24. august<\/strong>.<\/p>\n<p><!--more--><\/p>\n<p><strong>About Ingenuity Pathway Analysis<\/strong><\/p>\n<p><strong>\u00a0<\/strong>Ingenuity Pathway Analysis (IPA) is a powerful software that offers tremendous help when analysing and interpreting results obtained from various types of omics experiments. IPA offers the possibility to directly annotate and analyse the data, mapping it to functional pathways or disease networks, as well as searching for upstream regulators that may be involved in modulating the observed changes in a study. IPA is provided by QIAGEN Bioinformatics company (<a href=\"https:\/\/www.qiagenbioinformatics.com\/products\/ingenuity-pathway-analysis\/)\">https:\/\/www.qiagenbioinformatics.com\/products\/ingenuity-pathway-analysis\/)<\/a>.<\/p>\n<p>Advantages of IPA compared to other free online tools for pathway analysis<\/p>\n<ul>\n<li>IPA uses a manually curated database.<\/li>\n<li>IPA offers a range of features in one single software program, making it timesaving compared to using multiple software programs.<\/li>\n<li>IPA provides various visual representations that can be obtained from the analysis and transformed to publication-quality graphics.<\/li>\n<li>IPA can be upgraded with an advanced algorithm that can be used for discovering mechanisms of action or drug targets in the data by expanding upstream analysis to include regulators that are not directly connected to targets in the dataset.<\/li>\n<\/ul>\n<p>[:en]<a href=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-12616 alignleft\" src=\"http:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum-240x300.jpg\" alt=\"k2nytt_uke-33_anne-kristin-stavrum\" width=\"166\" height=\"208\" srcset=\"https:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum-240x300.jpg 240w, https:\/\/k2info.w.uib.no\/files\/2017\/08\/K2nytt_Uke-33_Anne-Kristin-Stavrum.jpg 400w\" sizes=\"auto, (max-width: 166px) 100vw, 166px\" \/><\/a>Is anyone interested in buying a license for the data analysis software <strong><a href=\"https:\/\/www.qiagenbioinformatics.com\/products\/ingenuity-pathway-analysis\/\">Ingenuity Pathways Analysis<\/a><\/strong>?, a<span id=\"result_box\" class=\"\" lang=\"en\"><span class=\"\">sks postdoctor Anne-Kristin Stavrum on behalf of her group, and writes on:<\/span><\/span><\/p>\n<p>At the beginning of July, we received some funding (<em>Sm\u00e5driftsmidler<\/em>) from the institute, and we would like to spend this money on a license for the data analysis software <em>Ingenuity Pathway Analysis<\/em> (IPA). A brief description of the program is given below.<\/p>\n<p>The funds we received from the institute do not cover the full amount of the license, so we have to add a little by ourselves. There are different types of licenses. The most relevant are licenses for one user or five users. Since a license for five users is only &laquo;a bit&raquo; more expensive than a single-user license, we would like to know if someone else at the institute might be interested in sharing the costs for a five-users-license.<\/p>\n<p>Exact price per license will depend on any additional packages that can be purchased, and any offer we may receive from <em>Qiagen<\/em>. The price will probably amount to NOK 13\u201315,000 per license, after deducting the amount we were awarded from the institute. The license will be valid for one year.<\/p>\n<p>Interested parties may contact <strong><a href=\"mailto:mailto:Anne-Kristin.Stavrum@uib.no\">Anne-Kristin Stavrum<\/a><\/strong> at the latest on Thursday 24 August.<\/p>\n<p><!--more--><\/p>\n<p><strong>About Ingenuity Pathway Analysis<\/strong><\/p>\n<p><strong>\u00a0<\/strong>Ingenuity Pathway Analysis (IPA) is a powerful software that offers tremendous help when analysing and interpreting results obtained from various types of omics experiments. IPA offers the possibility to directly annotate and analyse the data, mapping it to functional pathways or disease networks, as well as searching for upstream regulators that may be involved in modulating the observed changes in a study. IPA is provided by QIAGEN Bioinformatics company (<a href=\"https:\/\/www.qiagenbioinformatics.com\/products\/ingenuity-pathway-analysis\/)\">https:\/\/www.qiagenbioinformatics.com\/products\/ingenuity-pathway-analysis\/)<\/a>.<\/p>\n<p>Advantages of IPA compared to other free online tools for pathway analysis<\/p>\n<ul>\n<li>IPA uses a manually curated database.<\/li>\n<li>IPA offers a range of features in one single software program, making it timesaving compared to using multiple software programs.<\/li>\n<li>IPA provides various visual representations that can be obtained from the analysis and transformed to publication-quality graphics.<\/li>\n<li>IPA can be upgraded with an advanced algorithm that can be used for discovering mechanisms of action or drug targets in the data by expanding upstream analysis to include regulators that are not directly connected to targets in the dataset.<\/li>\n<\/ul>\n<p>[:]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[:no]Er noen interessert i \u00e5\u00a0 \u201dspleise\u201d p\u00e5 en lisens til dataanalyseprogrammet Ingenuity Pathways analysis?, sp\u00f8r postdoktor Anne-Kristin Stavrum p\u00e5 vegne av sin gruppe, og skriver videre: I begynnelsen av juli fikk vi tildelt en sum fra de interne sm\u00e5driftsmidlene som&hellip;<\/p>\n<p class=\"more-link-p\"><a class=\"more-link\" href=\"https:\/\/k2info.w.uib.no\/en\/2017\/08\/18\/spleiselag-pa-ingenuity-pathways-analysis\/\">Read more &rarr;<\/a><\/p>\n","protected":false},"author":3699,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-12588","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/12588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/3699"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=12588"}],"version-history":[{"count":2,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/12588\/revisions"}],"predecessor-version":[{"id":12617,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/12588\/revisions\/12617"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=12588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=12588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=12588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}